Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
Total Valuation
MoonLake Immunotherapeutics has a market cap or net worth of $1.30B. The enterprise value is $1.04B.
Market Cap$1.30B
Enterprise Value$1.04B
Share Statistics
MoonLake Immunotherapeutics has 70,847,404 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding70,847,404
Owned by Insiders36.85%
Owned by Institutions10.80%
Financial Efficiency
MoonLake Immunotherapeutics’s return on equity (ROE) is -0.75 and return on invested capital (ROIC) is -64.40%.
Return on Equity (ROE)-0.75
Return on Assets (ROA)-0.54
Return on Invested Capital (ROIC)-64.40%
Return on Capital Employed (ROCE)-0.65
Revenue Per Employee0.00
Profits Per Employee-2.29M
Employee Count100
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of MoonLake Immunotherapeutics is ―. MoonLake Immunotherapeutics’s PEG ratio is -0.04.
PE Ratio―
PS Ratio0.00
PB Ratio2.79
Price to Fair Value2.79
Price to FCF-4.33
Price to Operating Cash Flow-6.07
PEG Ratio-0.04
Income Statement
In the last 12 months, MoonLake Immunotherapeutics had revenue of 0.00 and earned -227.32M in profits. Earnings per share was -3.53.
Revenue0.00
Gross Profit-2.62M
Operating Income-244.83M
Pretax Income-229.71M
Net Income-227.32M
EBITDA-219.85M
Earnings Per Share (EPS)-3.53
Cash Flow
In the last 12 months, operating cash flow was -196.01M and capital expenditures -35.00K, giving a free cash flow of -196.04M billion.
Operating Cash Flow-196.01M
Free Cash Flow-196.04M
Free Cash Flow per Share-2.77
Dividends & Yields
MoonLake Immunotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.81
52-Week Price Change-50.15%
50-Day Moving Average16.06
200-Day Moving Average30.06
Relative Strength Index (RSI)62.35
Average Volume (3m)1.22M
Important Dates
MoonLake Immunotherapeutics upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateFeb 22, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
MoonLake Immunotherapeutics as a current ratio of 9.27, with Debt / Equity ratio of 24.86%
Current Ratio9.27
Quick Ratio9.27
Debt to Market Cap0.09
Net Debt to EBITDA1.18
Interest Coverage Ratio-33.78
Taxes
In the past 12 months, MoonLake Immunotherapeutics has paid 611.00K in taxes.
Income Tax611.00K
Effective Tax Rate>-0.01
Enterprise Valuation
MoonLake Immunotherapeutics EV to EBITDA ratio is -2.69, with an EV/FCF ratio of -3.01.
EV to Sales0.00
EV to EBITDA-2.69
EV to Free Cash Flow-3.01
EV to Operating Cash Flow-3.01
Balance Sheet
MoonLake Immunotherapeutics has $393.97M in cash and marketable securities with $75.71M in debt, giving a net cash position of $318.26M billion.
Cash & Marketable Securities$393.97M
Total Debt$75.71M
Net Cash$318.26M
Net Cash Per Share$4.49
Tangible Book Value Per Share$4.72
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for MoonLake Immunotherapeutics is $25.92, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$25.92
Price Target Upside41.48% Upside
Analyst ConsensusModerate Buy
Analyst Count13
Revenue Growth Forecast―
EPS Growth Forecast-157.74%